



VEO Ophthalmics Enters Strategic Partnership with PeriVision, Launches VisionOne™ AI Visual Field Platform in the U.S.

U.S. eye care specialists and their patients now have access to AI-powered VR visual field testing for improved speed and accuracy

WEST CHESTER, Ohio – October 16, 2025 – VEO Ophthalmics, LLC, today announced that the VisionOne™ VR Visual Field platform is now available in the United States through a strategic partnership between PeriVision (Switzerland) and VEO Ophthalmics, an industry leader of innovative ophthalmic technologies. The VisionOne™ utilizes PeriVision's patented AI visual field-testing algorithm (SORS) to optimize visual field tests, increasing efficiency and accuracy while decreasing testing time.

With VisionOne™, ophthalmologists and optometrists can perform visual field tests on portable VR headsets and subsequently analyze the results on a cloud platform. AI algorithms optimize the eye tests, automate assistance and quality control. At the core of the VisionOne™ lies PeriVision's patented visual field-testing algorithm SORS (Sequentially Optimized Reconstruction Strategy). VisionOne™ addresses the clinical need for more efficient and patient-friendly visual field testing, a routine eye test for glaucoma diagnosis and monitoring. In clinical studies it has demonstrated the ability to reduce test time dramatically, while maintaining high correlation with the gold standard and lower test / re-test variability.

VEO has entered into an exclusive agreement with PeriVision, the manufacturer of VisionOne™, to bring this technology into the U.S. market. "Just last year, a publication estimated that from 2020 to 2035, the ophthalmology workforce is expected to shrink by more than 2600 full-time equivalent (FTE), while demand will grow by around 5000 FTE. VisionOne™ addresses this drastically growing need for more efficient and patient-friendly ophthalmic testing. We are very excited to partner with VEO Ophthalmics to deliver our breakthrough technology to eye care professionals across the U.S.," said Patrick Kessel, CEO of PeriVision.

Ron Gilliland, President and CEO of VEO Ophthalmics, added, "VisionOne™ uniquely allows eye care professionals to reduce visual field testing time and maintain accuracy when diagnosing and monitoring glaucoma with advanced AI algorithms. We are very pleased to partner with PeriVision and bring this technology to eye care professionals to enhance patient care."

About PeriVision

PeriVision, an innovative spin-off from the University of Bern and the University Hospital Bern, is the developer and manufacturer of the VisionOne™ eye testing platform. VisionOne™ combines artificial intelligence (AI), virtual reality (VR) and the cloud to improve clinical productivity, assist in diagnostic decisions, and enhance access to eye testing. The company has won multiple awards such as the EIT Health Wild Card (2021) or the Switzerland TOP100 Startups and received several research grants from the Swiss federal government. To learn more, visit PeriVision at www.perivision.com.

About VEO Ophthalmics

Located in West Chester, Ohio, VEO Ophthalmics, LLC, is a developer and distributor of ophthalmic technologies. VEO focuses on improving patient care by partnering with leading ophthalmic surgeons to develop innovative tools for today's challenging surgical environment. Close relationships with ophthalmic healthcare customers and business partners help VEO ensure that its products and service experience meet the highest standards.

To learn more, visit VEO at www.veo-ophthalmics.com.